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Glutaminolysis drives membrane trafﬁcking to
promote invasiveness of breast cancer cells
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The role of glutaminolysis in providing metabolites to support tumour growth is well-
established, but the involvement of glutamine metabolism in invasive processes is yet to be
elucidated. Here we show that normal mammary epithelial cells consume glutamine, but do
not secrete glutamate. Indeed, low levels of extracellular glutamate are necessary to maintain
epithelial homoeostasis, and provision of glutamate drives disruption of epithelial morphology
and promotes key characteristics of the invasive phenotype such as lumen-ﬁlling and
basement membrane disruption. By contrast, primary cultures of invasive breast cancer cells
convert glutamine to glutamate which is released from the cell through the system Xc-
antiporter to activate a metabotropic glutamate receptor. This contributes to the intrinsic
aggressiveness of these cells by upregulating Rab27-dependent recycling of the transmem-
brane matrix metalloprotease, MT1-MMP to promote invasive behaviour leading to basement
membrane disruption. These data indicate that acquisition of the ability to release glutamate
is a key watershed in disease aggressiveness.
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A ltered cell metabolism is a hallmark of cancer. Cancer cellshave evolved a number of metabolic adaptations whichenable them to grow and divide under conditions that are
adverse to rapid cell proliferation1. Glucose and glutamine are key
nutrients that provide energy and generate biosynthetic inter-
mediates to produce macromolecules (amino acids and nucleo-
tides) indispensable for proliferation. In addition to its function as
a 'fuel', glutamine is also a key player in cytoprotective pro-
grammes that serve to 'buffer' insults encountered in the tumour
microenvironment2,3. First, glutamine contributes to the synth-
esis of glutathione (a tri-peptide of glutamate, cysteine and gly-
cine), an antioxidant molecule, by providing a source of
glutamate that serves a substrate for glutamate-cysteine ligase.
Secondly, glutamate allows import of cystine (another precursor
of glutathione) via the system Xc- antiporter that is driven by
equimolar export of glutamine-derived glutamate from the cell.
Finally, glutamine-derived metabolites are substrates of malate
dehydrogenase which generates NADPH, a molecule required to
keep glutathione in its reduced form2,3.
In addition to uncontrolled cell growth and proliferation,
carcinoma progression is accompanied by increased cell migra-
tion and invasion which drives cancer dissemination and
metastasis1. An accepted watershed in breast cancer aggressive-
ness is the progression from ductal carcinoma in situ (DCIS),
characterised by intraductal proliferation of malignant epithelial
cells with an intact basement membrane, to invasive ductal car-
cinoma (IDC) in which the basement membrane becomes brea-
ched allowing dissemination of malignant cells4. Despite this,
little is known about how altered energy metabolism of cancer
cells might contribute to basement membrane disruption and
subsequent migration of cancer cells from primary tumours.
Clinical data indicate that expression of the ASCT2 transporter5
and system Xc- antiporter6,7 (controlling glutamine uptake and
glutamate export respectively) are linked to metastasis and poor
prognoses, indicating that metabolic adaptations adopted by
cancer cells to support growth and to minimise oxidative stresses
may also contribute to cancer aggressiveness. In this study we
have found that high levels of glutamine consumption, in com-
bination with functional expression of the system Xc- antiporter,
contributes to cancer aggressiveness by generating a source of
extracellular glutamate. This extracellular glutamate then acti-
vates the GRM3 metabotropic glutamate receptor to drive
receptor recycling leading to basement membrane disruption and
invasion in breast cancer.
Results
Glutamate release drives invasive behaviour. Expression of the
polyoma middle T oncogene under control of the mammary
epithelial MMTV promoter (MMTV-PyMT) provides a reliable
model of breast cancer progression that recapitulates many
aspects of the human disease8, in particular luminal B-type breast
cancer9. To look for potential links between glutamine metabo-
lism and breast tumour progression we measured levels of glu-
tamine, glutamate and other metabolites in the serum of tumour-
bearing MMTV-PyMT mice and compared these with non-
tumour-bearing animals from the same genetic background.
Furthermore, we investigated whether the levels of these circu-
lating metabolites would correlate with mammary tumour bur-
den. This indicated that serum glutamate levels (but not
glutamine, glucose or lactate) become elevated in tumour-bearing
animals over a time course that follows tumour progression
(Fig. 1a), and that this correlates closely with tumour burden
(Fig. 1b). In addition, we have measured the circulating levels of a
broad range of metabolites during tumour progression in
MMTV-PyMT mice, and found that glutamate is the only one
whose serum levels positively correlate with primary mammary
tumour burden.
The tumour burden of MMTV-PyMT mice may constitute a
substantial proportion of body weight suggesting the possibility
that the source of elevated circulating glutamate may be the
tumour itself. To investigate this, we generated two low-passage
cell lines from MMTV-PyMT tumours (named PyMT#1 and
PyMT#2), isolated from different animals, which are highly
invasive in a range of ex vivo assays, form invasive tumours when
transplanted into the mammary fat pads of recipient mice, and
aggressively colonise the lung when introduced intravenously. We
measured glucose/glutamine consumption and lactate/glutamate
production in cells from invasive MMTV-PyMT tumours and
compared these with normal mouse mammary epithelial cells
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Fig. 1 Serum glutamate levels reﬂect mammary tumour burden in MMTV-PyMT mice. FVB/N mice, carrying a mouse mammary tumour virus (MMTV)
promoter-driven polyoma middle T (PyMT) transgene, were culled at 8, 10, 12 and 14 weeks of age and blood samples were collected via cardiac puncture.
Serum was isolated and the levels of the indicated metabolites determined using mass spectrometry a. Primary breast tumour burden was assessed at the
14 week time point by determination of total mammary weight and these were plotted against the plasma levels of glutamine, glutamate, glucose and
lactate b. Values are mean± SEM, *p= 0.05, **p< 0.01, Mann–Whitney test
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Fig. 2 Glutamate release through the system Xc- antiporter drives invasive behaviour. a, b MMTV-PyMT tumour-derived cell lines from two different animals
(PyMT#1, PyMT#2), MDA-MB-231 human breast cancer cells (MDA-MB-231) and normal murine mammary epithelial cells (NMuMG) were plated onto six-
well dishes at 1 × 105cells/well and grown towards conﬂuence for 3 days. Aliquots of cell-exposed medium were collected at 24 h intervals and glucose, lactate,
glutamine and glutamate concentration was determined. Values are mean± SEM, n= 3 independent experiments. In b cells were incubated for 24 h in full
DMEM (full), medium lacking glutamine (−Gln) or in the presence of sulphasalazine (SSZ; 200 μM), LY341495 (LY95; 100 nM), LY367385 (LY85; 15 μM),
(RS)-α-Cyclopropyl-4-phosphonophenylglycine (CPPG; 5 nM) or DMSO control. Values are normalised to glutamate release in full DMEM. Mean and SEM are
indicated, minimum of 3 independent experiments per conditions. ***p<0.001, **p<0.01 one-way ANOVA, Dunn’s multiple comparison test. c PyMT#1 or
MDA-MB-231 cells were plated into ﬁbroblast-derived extracellular matrix 4 h prior to imaging, in the presence of either full DMEM (full), glutamine-depleted
medium (−Gln), glutamine-depleted medium supplemented with 10 µM glutamate (−Gln + Glu) or 1 mg/ml glucose-containing medium (Low gluc.) and imaged
for 16 h by time-lapse microscopy. Where indicated, 200 μM sulphasalazine in the presence (SSZ+Glu) and absence (SSZ) of glutamate, or DMSO control
were added to full DMEM. Protrusion length measured with Image J, n= 3 independent experiments (whiskers: 5–95 percentile, + represents the mean)
(PyMT#1, full, −Gln, −Gln + Glu 540 cells; PyMT#1, DMSO, SSZ 360 cells, SSZ +Glu 200 cells, MDA-MB-231 full 338 cells, −Gln 349 cells, −Gln +Glu 354
cells; MDA-MB-231 DMSO, SSZ 358 cells, SSZ +Glu 123 cells) ***p<0.001 one-way ANOVA Dunn’s multiple comparison test. d PyMT#1 cells were plated
into Matrigel in full DMEM (full), glutamine-depleted medium (−Gln) or glutamine-depleted medium supplemented with 10 μM glutamate (−Gln +Glu) and
allowed to form organoids for 4 days before ﬁxation and visualisation of collagen IV (coll IV; green), F-actin (phalloidin; red) and cell nuclei (DAPI; blue) by
confocal microscopy. Bar, 20 μm. The circularity and area of organoids was determined using Image J. Mean and SEM are indicated, n= 3 independent
experiments (full 56 acini, −Gln 55 acini, −Gln + Glu 52 acini). ***p<0.001, two-way ANOVA Dunn’s multiple comparison test
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Fig. 3 Extracellular glutamate drives invasion through a type II metabotropic receptor. aMMTV-PyMT#1 tumour-derived cell lines or MDA-MB-231 cells were
plated into ﬁbroblast-derived extracellular matrix in full DMEM (full), in the presence of LY341495 (LY95; 100 nM), LY367385 (LY85; 15 μM), or (RS)-α-
Cyclopropyl-4-phosphonophenylglycine (CPPG; 5 nM) and invasive protrusion length determined as for Fig. 2c. Data are represented as box and whiskers plots
(whiskers: 5–95 percentile, + represents the mean), n= 3 independent experiments (PyMT#1 360 cells per condition; MDA-MB-231 full 359 cells, LY95 358
cells) ***p<0.001 one-way ANOVA, Dunn’s multiple comparison test (left graph) and Mann-Whitney test (centre graph). The right panel displays a dose-
inhibition response curve to a range of LY341495 (LY95) concentrations plotted on a log10 axis, n= 3 independent experiments (360 cells per condition), data
are mean± SEM. b PyMT#1 cells were plated into 3DMatrigel cultures in the presence of LY341495 (LY95; 100 nM) or DMSO control. After 4 days, cells were
ﬁxed and collagen IV (coll IV; green), F-actin (phalloidin; red) and cell nuclei (DAPI; blue) visualised by immunoﬂuorescence followed by confocal microscopy.
The circularity and area of the organoids was determined as for Fig. 2d. Bar, 20 μm. The mean and SEM are indicated, n= 3 independent experiments (DMSO
37 acini, LY95 42 acini). ***p<0.001, Mann–Whitney test. c The length of invasive protrusions emanating from PyMT#1 and MDA-MB-231 cells was
determined as for (a) in full DMEM (full), or in glutamine-depleted medium (−Gln) in the absence and presence of LY354740 (LY40; 50 nM) or quisqualate
(Quis; 1 μM). Data are represented as box and whiskers plots (whiskers: 5–95 percentile, + represents the mean), n= 3 independent experiments (PyMT#1 360
cells; MDA-MB-231 350 cells per condition) ***p<0.0001 one-way ANOVA, Dunn’s multiple comparison test. d PyMT#1 cells were plated into Matrigel in full
DMEM (full), glutamine-depleted medium (−Gln) or glutamine-depleted medium supplemented with LY354740 (LY40; 50 nM) and allowed to form organoids
for 4 days. Immunoﬂuorescence and quantiﬁcation is as for (b). Bar, 20 μm. The mean and SEM are indicated, n= 3 independent experiments (full 46 acini,
−Gln 45 acini, −Gln + LY40 43 acini). ***p<0.001, two-way ANOVA, Dunn’s multiple comparison test
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(NMuMG), and the well-established triple-negative invasive
human breast cancer cell line, MDA-MB-231. MMTV-PyMT
tumour-derived cell lines, NMuMG and MDA-MB-231 cells all
consumed glucose and glutamine (Fig. 2a). Moreover, both the
normal and invasive cell types produced lactate at levels that were
commensurate with their glucose consumption. Invasive cells
(PyMT#1, PyMT#2 & MDA-MB-231) released glutamate at rates
that also corresponded with their glutamine consumption, and
this was opposed by glutamine withdrawal indicating that
secreted glutamate is mostly derived from glutaminolysis (Fig. 2a,
b). In striking contrast, glutamate did not accumulate in the
medium surrounding breast epithelial cells (NMuMG) indicating
that these normal cells had reduced capacity to release glutamate,
despite their avid consumption of glutamine (Fig. 2a). MMTV-
PyMT tumour-derived cell lines express the SLC7A11 subunit
(also called xCT) of the system Xc- glutamate–cystine antiporter
at signiﬁcantly higher levels than NMuMG cells (Supplementary
Fig. 1a), suggesting that acquisition of expression of this
transporter might be responsible for increased glutamate release
from invasive cells. Indeed, inhibition of the Xc- antiporter
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with sulphasalazine (SSZ) potently opposed glutamate release
(Fig. 2b).
Breast cancer cells extend invasive protrusions when they
migrate into a ﬁbroblast-derived 3D extracellular matrix (ECM)
microenvironment which resembles the tumour stroma10, and
this key facet of invasiveness is opposed by pharmacological
inhibition or siRNA of the transmembrane matrix metallopro-
tease, MT1-MMP—as described below. We used this quantitative
and robust approach to investigate the contribution of glucose
and glutamate metabolism to invasive behaviour. Whilst MMTV-
PyMT tumour-derived cell lines extended invasive protrusions in
medium with reduced glucose concentration, depletion of
glutamine signiﬁcantly reduced protrusion length indicating that
glutaminolysis (but not glycolysis) contributes to invasiveness
(Fig. 2c; Supplementary Fig. 1c). Moreover, addition of
oligomycin did not affect protrusion length, indicating that the
requirement for glutamine in invasiveness is not due to its role in
the generation of Krebs cycle intermediates to fuel oxidative
phosphorylation (Supplementary Fig. 1d). Furthermore, addition
of SSZ to inhibit the system Xc- antiporter or siRNA of the Xc-
subunit xCT strongly reduced protrusion length (Fig. 2c;
Supplementary Fig. 1b). We, therefore, tested the requirement
for extracellular glutamate in invasiveness and found that
addition of glutamate signiﬁcantly restored the ability of
glutamine-deprived and SSZ-treated MMTV-PyMT and MDA-
MB-231 cells to extend invasive protrusions (Fig. 2c). It is
important to note that MDA-MB-231 and PyMT cells are unable
to grow in the absence of glutamine (Supplementary Fig. 1e),
and PyMT (but not MDA-MB-231) cells display moderately
increased cell death following withdrawal of glutamine (Supple-
mentary Fig. 1f). However, addition of glutamate at a concentra-
tion that modulates invasion did not inﬂuence cell death nor did
it support growth of glutamine-deprived cells, indicating that any
role played by extracellular glutamate under these conditions is
mediated via control of the cell migration/invasion machinery
and not by promoting cell growth or suppressing apoptosis
(Supplementary Fig. 1e,f).
MMTV-PyMT tumour-derived cells formed irregularly-shaped
organoids (with low circularity) in 3D cultures and although they
assemble the vestiges of collagen IV-rich basement membranes,
these structures are discontinuous and display marked breaches
through which cancer cells leave the organoid and disseminate
(Fig. 2d). When deprived of glutamine, however, PyMT cells
formed smaller organoids (reﬂecting their requirement for
glutamine to grow) bounded by an intact collagen-rich basement
membrane with high circularity (Fig. 2d). Addition of glutamate
to glutamine-starved organoids did not increase their size
(consistent with the inability of glutamate to support growth in
the absence of glutamine), but drove basement membrane
disruption and migration of cells out of the organoid which is
reﬂected by reduced circularity of the structure (Fig. 2d). Taken
together, these data indicate that although glutamine is essential
for efﬁcient growth of tumour cells and to oppose apoptosis, their
invasiveness is supported by an extracellular pool of glutamate
generated by glutaminolysis followed by its system Xc-
antiporter-mediated export into the extracellular milieu.
Glutamate drives invasion through the GRM3 receptor.
Metabotropic glutamate receptors (GRMs), are a family of G-
protein-coupled receptors established to mediate responses to
extracellular glutamate in the brain11, and these receptors have
also been linked to growth of malignant brain tumours (such as
glioma12,13) and other cancer types (for instance breast14 and
melanoma15,16). There are three groups of GRMs—groups I, II
and III. MMTV-PyMT tumour-derived cell lines, MDA-MB-231
cells and normal mammary epithelial cells express representatives
of each of these receptor subclasses (Supplementary Fig. 2a). We
tested the ability of inhibitors selective for these receptor sub-
classes to oppose extension of invasive protrusions in glutamine-
containing medium. An inhibitor of group II GRM receptors
(LY341495; subsequently referred to as LY95) strongly inhibited
extension of invasive protrusions in the low nM range (consistent
with the Ki of this compound for group II GRMs), whilst
antagonists of group I & III (LY367385 (LY85) & CPPG
respectively) receptor subclasses were ineffective in this regard
(Fig. 3a and Supplementary Fig. 2b). Consistently, following
blockade of group II GRMs (with LY95), PyMT cells grew in 3D
cultures as large spherical organoids (with high circularity) sur-
rounded by an intact collagen IV-rich basement membrane
(Fig. 3b). Furthermore, as the PyMT model most closely matches
the luminal B type of breast cancer, we used the ZR75-1 human
cell line which is derived from this form of the disease. ZR75-1
cells secrete glutamate17 (Supplementary Fig. 3a), express GRM3
(Supplementary Fig. 3b) and grew as irregularly-shaped orga-
noids in 3D cultures that displayed extensively disrupted base-
ment membranes (Supplementary Fig. 3d). Addition of LY95 to
these cultures signiﬁcantly opposed this invasive morphology and
led to generation of spherical organoids surrounded by a base-
ment membrane, indicating that group II GRMs contribute to
invasiveness in this luminal B-type human cell line (Supple-
mentary Fig. 3d).
Since blockade of group II GRMs opposes the invasive
behaviour of breast cancer cells, we then investigated the ability
Fig. 4 The GRM3 metabotropic receptor is required for glutamate-driven invasiveness. a An MMTV-PyMT tumour-derived cell line in which GRM3
expression had been disrupted by CRISPR gene editing (CRISPR-GRM3) and a corresponding pool that had been transfected with non-targeting CRISPR
guides (CRISPR-ctrl) were generated. CRISPR-GRM3 and CRISPR-ctrl cells were plated into ﬁbroblast-derived ECM to determine their ability to extend
invasive protrusions and these were analysed as for Fig. 2c. Data are represented as box and whiskers plots (whiskers: 5–95 percentile, + represents the
mean), n= 3 independent experiments (300 cells per condition). ***p< 0.001 one-way ANOVA, Dunn’s multiple comparison test. b CRISPR-Ctrl and
CRISPR-GRM3 cells containing an expression vector encoding ﬂag-tagged GRM3 (GRM3) or empty vector control (empty) were plated onto ﬁbroblast-
derived ECM and their ability to extend invasive protrusions was determined as for Fig. 2c. Data are represented as box and whiskers plots (whiskers: 5–95
percentile, + represents the mean), n= 3 independent experiments (300 cells per condition). ***p< 0.001 one-way ANOVA, Dunn’s multiple comparison
test. c CRISPR-Ctrl and CISPR-GRM3 cells were grown in 3D Matrigel cultures and their morphology and basement membrane integrity determined as for
Fig. 2d. Bar, 20 μm. The mean and SEM are indicated, n= 3 independent experiments. ***p< 0.001, **p< 0.01, one-way ANOVA, Dunn’s multiple
comparison test. d PyMT#1 or MDA-MB-231 cells were plated onto a collagen plug that had been pre-conditioned by primary human ﬁbroblasts and
allowed to invade for 6 days in the presence and absence of LY341495 (LY95; 100 nM) or DMSO control. Scale bar, 100 μm. At least 6 individual plugs per
condition were analysed in 3 independent experiments and the depth of cells invading was determined for each plug. Data are represented as box and
whiskers plots (whiskers: 5–95 percentile, + represents the mean), n= 3 independent experiments ***p< 0.001 two-sided Mann–Whitney test. e CRISPR-
Ctrl and CRISPR-GRM3 cells containing an expression vector encoding ﬂag-tagged GRM3 (GRM3) or empty vector control (empty) were plated onto
ﬁbroblast pre-conditioned collagen plugs and their invasion into these determined as for (d). Data are represented as box and whiskers plots (whiskers:
5–95 percentile, + represents the mean), n= 3 independent experiments *** p< 0.001 2-sided Mann-Whitney test
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of a group II GRM agonist to promote invasiveness. Indeed,
activation of group II GRMs with LY40 (but not activation of
group I GRMs with quisqualic acid), was sufﬁcient to restore
extension of invasive protrusions (Fig. 3c and Supplementary
Fig. 2c) and to drive basement membrane disruption and cell
dissemination without rescuing the impaired growth or
inﬂuencing apoptosis in glutamine-starved conditions (Fig. 3d;
Supplementary Fig. 1e, f).
GRM3 is the only member of the group II receptor subclass
expressed by MMTV-PyMT tumour-derived cell lines and MDA-
MB-231 cells (Supplementary Fig. 2a). We conﬁrmed that MDA-
MB-231 cells expressed GRM3 using western blotting
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(Supplementary Fig. 2d). However, we have been unable to obtain
an antibody capable of detecting the mouse GRM3 protein. We
tested the involvement of GRM3 in invasive responses by
generating MMTV-PyMT tumour-derived cells in which GRM3
expression is disrupted by CRISPR gene editing (CRISPR-GRM3)
(Supplementary Fig. 4a, b). CRISPR-GRM3 cells were completely
unable to extend invasive protrusions in response to addition of
glutamate (Fig. 4a, b), and grew as non-invasive organoids with
high circularity surrounded by collagen IV-rich basement
membranes when plated into 3D cultures (Fig. 4c). By contrast,
an MMTV-PyMT tumour-derived cell line that had been subject
in parallel to non-targeting CRISPR guides (CRISPR-ctrl) was
highly invasive in both these assays. Importantly, expression of
ﬂag-tagged human GRM3 (Supplementary Fig. 4c) completely
restored the ability of CRISPR-GRM3 cells to extend invasive
protrusions whilst having no inﬂuence on the protrusion length
of CRISPR-ctrl cells (Fig. 4b).
To further investigate the role of GRMs in breast cancer
invasive behaviour, we established organotypic cultures in which
tumour cells were plated onto the air-liquid interface of a collagen
type I matrix that had been preconditioned by human epidermal
ﬁbroblasts, an approach that recapitulates many of the key aspects
of the stromal microenvironment18,19. Inhibition of GRM3 with
LY95 signiﬁcantly opposed the ability of MMTV-PyMT tumour-
derived cell lines and MDA-MB-231 cells to invade this 3D
microenvironment (Fig. 4d). Furthermore, disruption of GRM3
using CRISPR signiﬁcantly opposed the ability of MMTV-PyMT
tumour-derived cells to invade into organotypic plugs, and this
was completely rescued by expression of ﬂag-tagged human
GRM3 (Fig. 4e).
GRM3 drives invasion via Rab27-dependent MT1-MMP recy-
cling. The transmembrane matrix metalloprotease, MT1-MMP is
a key initiator of proteolytic cascades that lead to invasiveness in
cancer. Indeed, MT1-MMP becomes concentrated in protrusive
‘invadopodial’ structures which are involved with the initial
penetration, destabilisation and breaching of collagen-rich base-
ment membranes surrounding epithelia20. Consistently, sup-
pression of MT1-MMP using inhibitors (GM6001) or siRNA
strongly suppressed extension of invasive protrusions when
MMTV-PyMT or MDA-MB-231 cells were plated into ﬁbroblast-
derived ECM (Fig. 5a; Supplementary Figure 5a, b), and com-
pletely opposed invasion of MMTV-PyMT cells into organotypic
plugs (Fig. 5b). To directly address the possibility that GRM3
promotes ECM degradation and/or remodelling, we plated MDA-
MB-231 cells onto a thin layer of ﬂuorescently-labelled gelatin
and measured the appearance of degraded foci (which correspond
to active invadopodia) underneath the cells. Consistent with
previous reports, addition of the MMP inhibitor GM6001 com-
pletely opposed degradation of gelatin by MDA-MB-231 cells
(Fig. 5c). Importantly, withdrawal of glutamine or addition of
LY95 also strongly opposed gelatin degradation, and addition of
glutamate completely restored the ability of glutamine-starved
cells to digest the ﬂuorescent gelatin matrix (Fig. 5c). Finally, we
used second harmonic generation (SHG) microscopy to deter-
mine the amount of ﬁbrillar collagen in organotypic plugs con-
taining MMTV-PyMT cells and found that they degrade the ECM
to generate areas with reduced ﬁbrillar collagen content (Fig. 5d).
CRISPR-mediated disruption or pharmacological blockade of
GRM3 using LY95 signiﬁcantly opposed the ability of MMTV-
PyMT cells to reduce the amount of ﬁbrillar collagen in orga-
notypic plugs indicating that GRM3 is required for breast cancer
cells to efﬁciently degrade the ECM in a 3D microenvironment
(Fig. 5d).
Endo-exocytic receptor trafﬁcking plays a key role in cancer
progression21. Regulation of endocytosis and recycling of integrin
and receptor tyrosine kinases contributes to the ability of
oncogenes, such as mutated forms of p53, to drive invasion and
metastasis22,23. Membrane trafﬁcking events are involved in the
breaching of basement membranes during normal tissue
morphogenesis, and DCIS to invasive tumour transitions in
cancer24,25. MT1-MMP function is inﬂuenced by how it is
trafﬁcked through the endosomal system26. A number of factors
control MT1-MMP trafﬁcking, and recently the Rab27 GTPase
was shown to be essential for the recycling of internalised MT1-
MMP from late endosomes to the plasma membrane to promote
invasiveness24. Knockdown of Rab27 opposed the ability of both
MMTV-PyMT and MDA-MB-231 cells to extend invasive
protrusions (Fig. 6a; Supplementary Fig. 5c, d), suggesting that
glutamate-driven receptor trafﬁcking might inﬂuence invasive-
ness through this GTPase. We, therefore, determined the
inﬂuence of glutamine metabolism on recycling of MT1-MMP,
and whether this is mediated via engagement of GRM3. In
glutamine-starved cells, internalised MT1-MMP was recycled
slowly to the plasma membrane (Fig. 6b). However, addition of
glutamate or the GRM3 agonist, LY40, drove a ~5 fold increase in
the rate of MT1-MMP recycling (Fig. 6b). Importantly, this was
opposed following blockade of GRM3 with LY95 and the rate of
MT1-MMP recycling became comparable to that of glutamine-
starved conditions (Fig. 6b; Supplementary Fig. 3c). Furthermore,
siRNA of Rab27 signiﬁcantly slowed glutamate-driven recycling
of MT1-MMP, and this was particularly apparent within 4 min of
glutamate addition (Fig. 6c). To investigate the kinetics of MT1-
Fig. 5 GRM3 drives MT1-MMP-dependent ECM degradation. aMDA-MB-231 cells or MMTV-PyMT#1 tumour-derived cells were transfected with siRNAs
targeting MT1-MMP (SMARTPool (SP) or individual oligos) or non-targeting control (NT). 24 h after transfection, cells were plated into ﬁbroblast-derived
extracellular matrix in full DMEM in the presence of GM6001 (5 μM) and invasive protrusion length determined as for Fig. 2c. Data are represented as box
and whiskers plots (whiskers: 5–95 percentile, + represents the mean), n= 3 independent experiments (PyMT#1 240 cells per condition; MDA-MB-231
245 cells per condition) ***p< 0.001 one-way ANOVA, Dunn’s multiple comparison test. b MMTV-PyMT#1 cells were plated onto a collagen plug that
had been pre-conditioned by primary human ﬁbroblasts and allowed to invade for 6 days in the presence and absence of GM6001 (5 μM) or DMSO
control. Image representative of n= 2 independent experiments. Bar, 100 μm. c MDA-MB-231 cells were plated onto glass surfaces that had been pre-
coated with FITC-conjugated gelatin (green signal) in either full DMEM (full)—in the presence and in the absence of LY341495 (LY95; 100 nM) or
GM6001 (5 μM)—or in glutamine-depleted medium (−Gln), or glutamine-depleted medium supplemented with 10 µM glutamate (−Gln + Glu). 16 h
following plating, cells were ﬁxed and stained with phalloidin (red signal) and DAPI (blue signal) and visualised using ﬂuorescence confocal microscopy.
Bar, 20 μm. The area of degraded gelatin (black signal) was determined using Image J and corrected for cell number. Data are represented as box and
whiskers plots (whiskers: 5–95 percentile, + represents the mean), n= 3 independent experiments (> 40 cells per condition) ***p< 0.001, **p< 0.01, *p<
0.05 one-way ANOVA, Dunn’s multiple comparison test. d PyMT#1, CRISPR-Ctrl., and CRISPR-GRM3 cells were plated onto a collagen plug that had been
pre-conditioned by primary human ﬁbroblasts and allowed to invade for 6 days in the presence and absence of LY341495 (LY95; 100 nM) or DMSO
control. The plugs were then imaged using second harmonic generation (SHG) microscopy to visualise ﬁbrillar collagen. The level of the SHG signal was
then calculated using image J. Data are represented as box and whiskers plots (whiskers: 5–95 percentile, + represents the mean), n= 3 independent
experiments (18 plugs per condition) **p< 0.01, *p< 0.05 one-way ANOVA, Dunn’s multiple comparison test. Bar, 37.5 μm
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MMP recycling in greater detail, we expressed mCherry-tagged
MT1-MMP in MDA-MB-231 cells and used total internal
reﬂectance ﬂuorescence (TIRF) microscopy followed by image
analysis to quantify the arrival of MT1-MMP-containing vesicles
at the ventral plasma membrane. Addition of glutamate,
compared to vehicle treated controls, drove a signiﬁcant increase
in the recruitment of MT1-MMP-positive vesicles to the ventral
plasma membrane ~2–4 min following treatment (Fig. 6d). This
was completely opposed by siRNA-mediated knockdown of
Rab27 (Fig. 6e).
Glutamate drives invasiveness of mammary epithelial cells.
Normal mammary epithelial cells express low levels of xCT and
secrete far less glutamate compared to invasive MMTV-PyMT
and MDA-MB-231 cells (Fig. 2a; Supplementary Fig. 1a). How-
ever, because normal mammary epithelial cells express GRM3
(Supplementary Fig. 2a), it is possible that they are able to
respond to extracellular glutamate by recycling MT1-MMP and
mounting an invasive response. We transfected NMuMG cells
with mCherry-tagged MT1-MMP and monitored its delivery to
the plasma membrane using TIRF microscopy. Addition of
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glutamate to NMuMG cells led to a signiﬁcant increase in
recruitment of MT1-MMP vesicles to the plasma membrane
(Fig. 7a) which was opposed by siRNA of Rab27 (Fig. 7b). In 3D
cultures, mammary epithelial cells polarise to form spherical
organoids (with high circularity) encircling a well-deﬁned inter-
nal lumen (~60% of organoids possess a single lumen) bounded
externally by a collagen IV-rich basement membrane (Fig. 7c).
However, addition of glutamate led to discontinuities and brea-
ches in the basement membrane with cells invading into the
surrounding ECM (Fig. 7c). More surprisingly perhaps, addition
of extracellular glutamate perturbed mammary epithelial polar-
isation as evidenced by a loss of single lumen structures (Fig. 7c).
The ability of glutamate to drive basement membrane disruption
and lumen-ﬁlling in NMuMG cells was completely dependent on
GRM3 activity since this was reversed following blockade with
LY95. Furthermore, MT1-MMP inhibition (with GM6001) or
siRNA of MT1-MMP or Rab27 were sufﬁcient to protect
NMuMG cells from the transforming effects of glutamate
(Fig. 7d,e; Supplementary Fig. 6a–c). Taken together, these data
indicate that extracellular glutamate acts via GRM3 to promote
invasive phenotypes in normal mammary epithelial cells by
upregulating Rab27-dependent recycling of MT1-MMP.
Discussion
Here we have shown that glutaminolysis can drive cancer inva-
siveness by increasing glutamate levels in the extracellular milieu.
This, in turn, activates a metabotropic glutamate receptor to
promote trafﬁcking of a pro-invasive transmembrane matrix
metalloprotease (Fig. 8). Cells from the normal mammary epi-
thelium and those from invasive breast tumours consume gluta-
mine at similar rates indicating that it is not upregulation of
glutaminolysis itself that promotes invasiveness. Rather, acquisi-
tion of the expression of Xc- antiporter subunit xCT and release
of glutamate through this channel dictates the transition between
indolent and aggressive behaviours. The system Xc- antiporter is
a key target of a cytoprotective/antioxidant transcriptional pro-
gramme controlled by the NRF2 transcription factor27, and its
role in this regard is to uptake cystine to support increased glu-
tathione synthesis. Such cytoprotective programmes are com-
monly upregulated in cancer and this is thought to engender fast
growing and chemoresistant tumours28. Because system Xc-
antiporter also exports glutamate, an additional consequence of
the NRF2 programme would be increased GRM3-driven inva-
siveness. Targeting cytoprotective programmes is being
considered as a strategy for opposing tumour growth, but our
ﬁndings indicate that blockade of system Xc- antiporter may also
be effective in reducing tumour aggressiveness and this should be
considered when drugs such as SSZ are evaluated clinically.
GRM signalling has been linked to pathogenesis in a number of
cancer types, including brain tumours12,13,29,30, melanoma16 and
breast cancer14,15,31. These studies have mostly linked activation
of signalling downstream of GRMs (for example, protein kinase
C, PI-3 kinase and MAP kinases) to cell growth and inhibition of
apoptosis. Additionally, mutations in GRM3 that lead to con-
stitutive receptor activation have been shown to provide cell
proliferation and survival signals in melanoma16. Throughout
these reports there are indications that cell migration may be
affected by activation of GRM signalling, but the mechanisms that
mediate this and whether this is linked to invasive behaviour is
not clear. Although we have not been able to demonstrate any
clear connection between extracellular glutamate and breast
tumour cell growth or resistance to apoptosis, we ﬁnd that the
GRM3 metabotropic glutamate receptor is intimately linked to
invasive behaviour. Moreover, we show for the ﬁrst time that
GRM signalling can inﬂuence vesicular trafﬁcking and, speciﬁ-
cally, that GRM3 activation fosters the endosomal trafﬁcking of a
pro-invasive transmembrane matrix metalloprotease—a process
dependent on Rab27, a GTPase linked to poor prognosis and
metastasis in breast cancer and glioma32,33. In the brain, ligation
of GRM3 inﬂuences presynaptic function by suppressing the
activity of adenylate cyclase to decrease cAMP formation and
PKA activation34. This raises the fascinating possibility that
cAMP signalling is a negative regulator of invasiveness in breast
cancer, and further work will be necessary to elucidate how this is
linked to trafﬁcking of MT1-MMP and possibly to other pro-
invasive receptors that cycle through the endosomal system.
Circulating glutamate levels have been known for some time to
be elevated in breast and prostate cancer patients and have been
linked to poor prognosis35,36. Indeed, we have found that gluta-
mate (but not glutamine, glucose or lactate) levels increase sig-
niﬁcantly in the serum of tumour-bearing MMTV-PyMT mice by
comparison with non-tumour-bearing control animals, and this
correlates temporally with tumour progression and tumour bur-
den. These data indicate a causal relationship between breast
tumour burden and circulating glutamate concentration. How-
ever, the provenance of increased serum glutamate in cancer
patients is not clear. The relationship between serum and intra-
tumoural metabolite levels is unlikely to be straightforward, and
currently it is technically challenging to measure the extracellular
Fig. 6 Extracellular glutamate drives Rab27-dependent recycling of MT1-MMP. a MDA-MB-231 cells and MMTV-PyMT tumour-derived cells (PyMT#1)
transfected with siRNAs targeting Rab27 (SMARTPool (SP) or individual oligos) or non-targeting control (NT) were plated 24 h after transfection into
ﬁbroblast-derived extracellular matrix in full DMEM and invasive protrusion length determined as for Fig. 2c. Data are represented as box and whiskers
plots (whiskers: 5–95 percentile, + represents the mean), n= 3 independent experiments (PyMT#1> 200 cells; MDA-MB-231,> 250 cells) *** p< 0.001
**p< 0.01 one-way ANOVA, Dunn’s multiple comparison test. b, c MDA-MB-231 cells were transfected with siRNAs targeting Rab27 (siRab27) or non-
targeting control (siNT) (c), or left untransfected (b). 96 h following transfection, cells were starved of glutamine for 90min then surface-labelled with
0.13 mg/ml NHS-S-S-Biotin at 4 °C and internalisation was then allowed to proceed for 30min at 37 °C. Biotin remaining at the cell surface was removed
by exposure to MesNa at 4 °C, and internalised MT1-MMP chased back to the cell surface at 37 °C for the indicated times in the absence (−Gln) or
presence of 15 μM glutamate (−Gln + Glu), or 50 nM LY354740 (−Gln + LY40) or glutamine-deprived media supplemented with 15 μM glutamate in the
presence of 100 nM LY341495 (−Gln + Glu + LY95) or in full DMEM (full). Cells were then re-exposed to MesNa and biotinylated MT1-MMP determined
by capture-ELISA with anti-human MT1-MMP antibodies. The proportion of MT1-MMP recycled to the plasma membrane is expressed as % of the pool of
MT1-MMP labelled during the internalisation period. n= 3 independent experiments for full, –Gln and –Gln + Glu, values are mean± SEM; n= 2 for –Gln +
LY40 and –Glu + Glu + LY95, values are mean; n= 3 for –Glu + Glu; siNT and –Glu + Glu; siRab27, values are mean± SEM. ***p< 0.001 Dunn’s multiple
comparison test. d,e MDA-MB-231 cells transfected with mCherry-tagged-MT1-MMP in combination with siRNAs targeting Rab27 (siRab27) or non-
targeting control (siNT) as indicated, and plated onto ﬁbronectin-coated glass-bottom dishes. 18 h following transfection, medium changed for DMEM
lacking serum and glutamine and cells imaged by TIRF microscopy. Frames were collected every 1.5 s, and glutamate (20 μM) or vehicle added at the
indicated time. Image J (TrackMate plugin) was used for quantiﬁcation. Values were normalised by subtracting the average rate 1–2 min prior to vehicle or
glutamate addition. Kymographs display time on the horizontal axis and distance on the vertical axis. Values are mean± SEM; n= 3 independent
experiments. *** p< 0.001 two-way ANOVA, Dunn’s multiple comparison test
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concentration of glutamate within tumours and tissues. In the
brain, glutamate released by glutamatergic neurones is removed
from the synaptic cleft and extrasynaptic sites via uptake into glial
cells37, and it is possible that mechanisms exist in epithelia to
sequester glutamate to avoid activation of GRMs on epithelial cell
that could lead to dysplasia. Furthermore, stromal cells may
inﬂuence glutamate levels in tumours and we have already
observed that carcinoma-associated ﬁbroblasts are capable of
releasing considerable quantities of glutamate, and this would be
likely to contribute to the stromal drive to tumour invasiveness.
Finally, because GRM3 is expressed in a number of non-epithelial
cell types it is probable that increased serum glutamate levels
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occurring in tumour-bearing animals may inﬂuence metastasis by
activating GRM3 in immune cells, such as neutrophils and
macrophages, that contribute to the seeding of metastases. We
had approached this question by injecting MMTV-PyMT cells
into the tail vein of mice and monitoring the ability of these to
colonise the lung. We found that, although treatment of mice
with LY95 signiﬁcantly opposed lung colonisation (Supplemen-
tary Fig. 7), deletion of GRM3 in the MMTV-PyMT cells by
CRISPR was not reproducibly effective in this regard. This indi-
cates that, although GRM3 directly contributes to invasiveness of
breast tumour cells and their ability to breach basement mem-
branes, the contribution made by GRM3 to extravasation and
metastatic seeding of disseminated cancer cells is more likely to
be mediated via effects on other cell types.
Overall, our study has identiﬁed a new link between tumour
cell metabolism and the invasive behaviour of tumour cells, and
indicates that drugs capable of interfering with glutamate release
or GRM receptor function may be useful in combatting tumour
progression. We also shed light on a new link between GRM
signalling and vesicular trafﬁcking, although more work is
required to understand how GRM downstream signalling impacts
the endosomal recycling machinery. Future work will be required
to accurately determine the extracellular concentrations of glu-
tamate within tumours and to evaluate the relationship between
this and glutamate levels in the general circulation to allow
clinicians to devise focused treatments that prevent metastatic
disease.
Methods
Cells and reagents. MDA-MB-231 cells (obtained from ATCC) were kept in a
humidiﬁed incubator at 5% CO2, in DMEM with 10% foetal calf serum, 2 mM
glutamine and antibiotics. For NMuMG cells, the media was supplemented with
10 μg/ml insulin. For PyMT cells, the media was supplemented with 20 ng/ml EGF
and 10 μg/ml insulin. Although MDA-MB-231 cells have previously been reported
to express GRM131, there are a number of different strains of this cell line which
are known to differ in their invasive characteristics. By using a cDNA library from
human brain as a positive control, we have carefully tested the strain of MDA-MB-
231 cells that we have used and found that they do not express GRM1 at detectable
levels.
ZR75-1 cells (obtained from ATCC) were kept in a humidiﬁed incubator at 5%
CO2, in RPMI medium supplemented with 10% foetal calf serum, 2 mM glutamine
and antibiotics. MDA-MB-231, ZR75-1 and in-house lines derived from MMTV-
PyMT tumours were routinely tested for mycoplasma contamination using the
Beatson Institute’s in-house mycoplasma testing service.
To isolate cell lines from the PyMT model, mice expressing the MMTV-PyMT
transgene were culled by CO2 euthanasia. Tumours were then surgically excised
and minced using a McIlwain tissue chopper. Minced tumour specimens were
transferred to DMEM supplemented with 10% foetal calf serum, 20 ng/ml EGF, 10
μg/ml insulin, 2 mM glutamine and antibiotics. PyMT#1 and PyMt#2 cells were
generated in this way from two separate mice and maintained in the above medium
for a maximum of 20 passages.
To generate GRM3-CRISPR cells, speciﬁc guides targeting the exon containing
the glutamate binding region were designed using Zhang’s laboratory algorithm
(http://crispr.mit.edu/). CRISPR guides were produced using the GeneArt®
CRISPR Nuclease Vector Kit (Life Technologies Cat A21174) and transfected using
Amaxa nucleofector 2b (Lonza) according to manufacturer’s protocol. Cells were
then sorted with an Aria sorter Z6001 (BD Biosciences). CRISPR cleavage kit was
used to verify recombination according to manufacturer instructions. Brieﬂy,
primers were designed to amplify a 500 bp amplicon containing the CRISPR site.
Cas9 activity will generate a smaller fragment around 400 bp.
To generate rescue cell lines, CRISPR-Ctrl and CRISPR-GRM3 cell lines were
transfected with human Flag-GRM3 (Addgene, Plasmid #31798) or empty CMV-
Flag plasmid. Stable cell lines were also generated by keeping the transfected cells in
presence of 1 μg/ml puromycin for 2 weeks.
LY 367385 (selective GRM1 antagonist), CPPG (group III GRM antagonist), LY
341495 (group II GRM antagonist) and LY 354740 (selective group II GRM
agonist) were from TOCRIS. Oligomycin, GM6001 and sulphasalazine were from
Sigma. siRNAs were from Dharmacon.
In vivo experiments. For determination of metabolite concentration in tumour-
bearing animals, we used FVB/N female mice (>20 generations inbred), carrying a
mouse mammary tumour virus (MMTV) promoter-driven polyoma middle T
(PyMT) transgene38. Animals were culled at 8, 10, 12 and 14 weeks of age. Blood
samples were collected via cardiac puncture following euthanasia using CO2. Serum
was isolated by allowing blood to clot for 5 min at room temperature and then
centrifuging at 10,000 × g for 15 min. Samples were then stored at −80 °C prior to
metabolite extraction in a buffer containing 50% methanol, 30% acetonitrile, 20%
water followed by mass spectrometric analysis by LC-MS using HILIC chroma-
tography with full scan mass spectrometry on a Thermo Q-Exactive instrument,
measuring metabolites across a mass range of 75–1000 Da.
For tail vein injection, 0.5 × 106 cells in 100 μl PBS were injected into CD1-nu/
nu recipient mice (Charles River, UK). Mice were culled when they presented signs
of metastasis. LY95 (10 mg/kg/day) or PBS control was administered daily by
subcutaneous injection as described in12.
All experiments were performed following relevant guidelines and regulations,
in accordance to the ethical approval from Glasgow University, under the revised
Animal (Scientiﬁc Procedures) Act 1986 and the EU Directive 2010/63/EU (PPL
70/8645). Animals were housed in individual cages, ventilated in a barrier facility
and containing environmental proactive enrichment.
Measurement of metabolites in cultured cells. Cells were plated at 105 cells per
well in six-well plates. 24 h after plating, culture media was removed and replaced
with full medium with or without indicated treatments, or medium deprived of
glutamine. Cell growth was monitored and culture supernatants were harvested
over a 4 day period and frozen at −80 °C. The concentration of glutamate, glucose,
lactate and glutamine in the cell-exposed supernatants was then determined using a
2950 Biochemistry analyser (YSI).
Determination of invasiveness. Fibroblast-derived ECM were generated as
described in10, but using human immortalised ﬁbroblast as described in18. Cells
were seeded into ﬁbroblast-derived ECM in six-well plates 4 h prior to imaging by
time-lapse phase contrast microscopy (Axiovert S100; Carl Zeiss Micro-Imaging,
10× objective) in an atmosphere of 5% CO2 at 37 °C, as described in 39. Protrusion
elongation was measured using Image J software. Cells were depleted of glutamine
(with or without the addition of glutamate) for 4 h prior to imaging. Because
PyMT cells extend protrusions at both ends of the cell, the total protrusion lengths
(i.e., the length of all invasive protrusions emanating from the cell) were combined,
whereas for MDA-MB-231 cells only the length of the unique front protrusion in
the direction of migration was measured.
Three-dimensional culture of PyMT#1 cells was performed as described in 40.
5 × 103 cells were plated into Matrigel. Following plating, cells were incubated in
DMEM with or without glutamine and the indicated supplements (glutamate,
LY40, or LY95) for 4 days, prior to ﬁxation with 2% paraformaldehyde and
permeabilisation with 0.5% triton-X100. For 3D culture of normal mammary
epithelial cells, NMuMG cells were plated into Matrigel containing 1.6 mg/ml rat
tail collagen I. Following culture in full DMEM for 4 days, the medium was
changed for DMEM or DMEM supplemented with 10 μM glutamate or LY354740
(LY40; 50 nM) and the cells were cultured for a further 4 days prior to ﬁxation.
Fig. 7 Normal mammary epithelial cells respond to extracellular glutamate by mobilising MT1-MMP to drive an invasive morphology. a, b Normal
mammary epithelial (NMuMG) cells were transfected with mCherry-tagged MT1-MMP in combination with siRNAs targeting Rab27 (siRab27) or non-
targeting control (siNT) as indicated, and plated onto Matrigel-coated glass-bottomed dishes. The rate of recruitment of vesicle positive for mCherry-MT1-
MMP to the TIRF ﬁeld was determined as for Fig. 6d, e. ***p< 0.001 **p< 0.01 two-way ANOVA, Dunn’s multiple comparison test. c,e NMuMG cells were
transfected with siRNAs targeting MT1-MMP (siMT1-MMP), Rab27 (siRab27) or non-targeting control (siNT) as indicated (d, e) or were left
untransfected (c). Cells were plated into 3D Matrigel plugs containing 1.6 mg/ml rat tail collagen I. Following culture in full DMEM for 4 days, the medium
was changed for full DMEM or full DMEM supplemented with 10 μM glutamate with or without LY341495 (LY95; 100 nM) and cultured for a further
4 days. Immunoﬂuorescence and circularity measurements were as for Fig. 2d. Bar, 20 μm. Circularity data are represented as box and whiskers plots
(whiskers: 5–95 percentile, + represents the mean), n= 3 independent experiments ***p< 0.001 **p< 0.01 *p< 0.05 one-way ANOVA, Dunn’s multiple
comparison test (full 97 acini, + Glu 80 acini, + Glu + LY95 94 acini; siNT + Glu 101 acini, siMT1-MMP + Glu 109 acini, siMT1-MMP-Glu 72, acini, siRab27 +
Glu 68 acini, siRab27-Glu 69 acini). The proportion of organoids displaying single lumen was determined by examination of the F-actin distribution across a
series of Z-planes using confocal microscopy. Values are mean± SEM, n= 3 independent experiments. ***p< 0.001 **p< 0.01 one-way ANOVA Tukey’s
comparison test
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Antibodies used for immunoﬂuorescence staining were as follow: anti-Collagen IV
antibody (Abcam, ab19808); Donkey anti-Rabbit IgG conjugated with Alexa Fluor
488 (ThermoFisher, A-21206). Alexa Fluor 546 Phalloidin (ThermoFisher,
A22283) was used to stain F-actin. Images were acquired using an Olympus
FV1000 confocal microscope, 60× objective, 1.4 NA and circularity was quantiﬁed
using the 'Descriptors' plugin in Image J software.
Organotypic invasion assays were performed as previously described18. Brieﬂy,
human epidermal ﬁbroblasts were seeded in plugs of rat tail collagen 1 which were
allowed to contract in full DMEM (DMEM supplemented with 10% FCS and 2 mM
glutamine) for 14 days. 4 × 105 cells were then plated on top of these plugs and
cultured for 2 days. Plugs were then transferred to a metal grid and cultured with
full DMEM with or without LY95 for 1 week followed by ﬁxation in 4%
paraformaldehyde before parafﬁn embedding. 4 μm sections were then cut and
stained using Hematoxylin and Eosin.
Recycling assays. MDA-MB-231 cells were incubated in serum-free DMEM in the
absence of glutamine for 1.5 h, transferred to ice, washed twice in cold PBS and
surface-labelled at 4 °C with 0.2 mg/ml NHS-SS-biotin (Pierce) in PBS for 30 min.
Cells were transferred to serum and glutamine-free DMEM for 30 min at 37 °C to
allow internalisation of tracer. Cells were returned to ice, washed twice with ice-
cold PBS and biotin was removed from proteins remaining at the cell surface by
reduction with MesNa. The internalised fraction was then chased from the cells by
returning them to 37 °C in serum-free DMEM in the absence or presence of 15 μM
glutamate, with or without LY40, or LY95 as indicated. At the indicated times, cells
were returned to ice and biotin removed from recycled proteins by a second
reduction with MesNa. Biotinylated MT1-MMP was then determined by capture-
ELISA using Maxisorp (Nunc) plates coated with antibodies recognising human
MT1-MMP.
TIRF microscopy. Cells expressing mCherry-MT1-MMP were seeded onto 3.5 cm
glass-bottomed plates coated with either ﬁbronectin (for MDA-MB-231) or
Matrigel (for NMuMG) 18 h prior to imaging. Media was changed for DMEM
lacking serum and glutamine and cells imaged in an atmosphere containing 5%
CO2 at 37 °C using either a 100X or 60X Plan Apo TIRF objective mounted onto a
Nikon Eclipse Ti microscope. To generate time-lapse movies, cells were imaged
every 1.5 s. Glutamate or vehicle control was added as a 10× spike 5 min after
image collection had commenced. To determine the rate of vesicle recruitment,
Image J software (incorporating the TrackMate plugin) was used to calculate the
rate at which mCherry-MT1-MMP positive vesicles arrived at the TIRF ﬁeld.
Fluorescent gelatin degradation. Acid washed coverslips (19 mm diameter) were
coated with 0.005% w/v poly-lysine for 20 min at room temperature, washed with
PBS and coated with 80 μl of 1 mg/ml Oregon green 488-conjugated gelatin (Life
Technologies). Coverslips were left in the dark for 20 min, washed and crosslinked
with 0.5% glutaraldehyde. Coated coverslips were then blocked with 20 mM gly-
cine, sterilised in 70% w/v ethanol and quenched for 1 h in DMEM before addition
of MDA-MB-231 cells. Cells were treated with the indicated treatments for 18 h,
ﬁxed and stained with DAPI and Alexa Fluor 555 Phalloidin (Life Technologies).
Images were collected using an Olympus FV1000 confocal microscope. To quantify
degradation, images were processed using the Image J Threshold and Analyse
Particles functions. For each ﬁeld, the total degradation area (black pixels), was
divided by the total number of cells.
SHG imaging. Collagen second harmonic generation (SHG) images from 4% PFA-
ﬁxed organotypic plugs were collected using a LaVision Biotec Trim‐scope with a
Coherent Chameleon Ti:Sapphire femtosecond pulsed laser. An excitation wave-
length of 890 nm was used for generating SHG signal at 445 nm. A z‐stack
encompassing a depth of 10 μm was imaged over a region of 150 μm by 150 μm,
with at least seventeen pictures per condition in two independent experiments
being taken and analysed using Image J. For each depth, the image was auto-
matically thresholded and the percentage of ﬁbrillar collagen coverage was deter-
mined by quantifying the percentage of positive SHG pixels. The % of ﬁbrillar
collagen coverage was then plotted for each depth and the area under curve was
calculated as a readout of SHG signal.
Quantitative PCR. Primers for human GRM1, 2, 3, 4, 5 and 7 were from ref.12.
Sequence of GRM6 (Forward: 5′-CCCAGTCAGCTGAAAAGATCTACA-3′;
Reverse: 5′-CGCTTTCGCTTCTGCACATT-3′) and GRM8 primers (Forward: 5′-
TGAAACCAACACTTCCTCTACCA-3′; Reverse: 5′-TCCAGGAGT-
GAATTTTTGCGG-3′) were designed using NCBI PrimerTool.
Primers for mouse GRMs were obtained from the Primer Bank, primer ID are as
follows: GRM1 (34328063a1), GRM2 (29611608a1), GRM3 (32469489a1), GRM4
(29611479a1), GRM5 (26346991a1), GRM6 (197333818c1), GRM7 (26343463a1)
and GRM8 (116812903c1). All primers, except for GRM8 had validation data
available on the website (https://pga.mgh.harvard.edu/primerbank/).
QuantiTect primer assays (Qiagen) were used for mouse Rab27A (Cat no.
QT00119392), human Rab27A (Cat no. QT00040054), human GAPDH (Cat no.
QT01192646) and mouse β-actin (Cat no. QT01136772) detection. RT2 qPCR
Primer Assays (Qiagen) were used for mouse xCT (Cat no. PPM 41938 C) and
MT1-MMP (Cat no. PPM03611D) detection.
Data availability. The data supporting the ﬁndings of this study are available
within the article and its supplementary information ﬁles and from the corre-
sponding authors upon reasonable request.
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